|MDACC Study No:||2009-0570 (clinicaltrials.gov NCT No: NCT01692197)|
|Title:||A Phase 2 Study of E7070, Idarubicin and Cytarabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes|
|Principal Investigator:||Gautam Borthakur|
|Treatment Agent:||Cytarabine; Dexamethasone; E7070; Idarubicin|
|Study Description:||The goal of this clinical research study is to learn if E7070 given alone or in |
combination with idarubicin, cytarabine, and dexamethasone can help to control
the disease in patients with either AML or high-risk MDS that has relapsed.
The safety of the study drug/study drug combination will also be studied.